Skip to main content

The U.S. Food and Drug Administration (FDA) has granted SuperGen, Inc. orphan drug designation for their targeted agent MP-470 in the treatment of glioblastoma multiforme.

MP-470 is a tyrosine kinase inhibitor targeted against c-MET, c-RET, and the Rad51 protein, as well as mutant forms of c-KIT, PDGFR, and FLT3.

MP-470 is now being evaluated in Phase I trials as both a single agent and in combination with chemotherapy for the treatment of solid tumors. A Phase Ib trial is evaluating its efficacy in glioblastoma.

Scroll to Continue

Recommended Articles

Image placeholder title

Treatment of HER2+ Colorectal Cancer With Precision Cancer Medicines

Precision medicines targeting HER2 are available; Enhertu side effects are significant.

Image placeholder title

Bispecific Antibody Precision Immunotherapy in non-Hodgkin lymphoma

Epcoritimab and other bi-specific antibody immunotherapies effective in refractory NHL - New option for elderly patients?

Image placeholder title

Recognize The Early Signs of Skin Cancer

Learn to identify the early signs of skin cancer and perform your self skin examinations for early detection.